Loading news...
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Twin Capital Management Inc. decreased its position in Hologic, Inc. (NASDAQ: HOLX) by 77.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,337 shares of the medical equipment provider's stock after selling 18,345 shares during the quarter. Twin
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio.
Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.03 per share a year ago.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2026.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
HOLX heads into Q1 earnings with rising EPS and revenue estimates, strong segment momentum and a pending buyout limiting near-term upside.
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
HOLX's GYN Surgical unit, boosted by MyoSure, Fluent and Gynesonics, drives 10.2% revenue growth and is likely to lift upcoming Q1 results.
Hologic and Stryker gear up for earnings with diagnostic wins, surgical growth and strategic moves shaping the medical device race.
NEW YORK, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hologic, Inc.
/PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the